New York State Teachers Retirement System cut its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) by 0.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 31,666 shares of the company’s stock after selling 300 shares during the period. New York State Teachers Retirement System owned 0.10% of Medpace worth $4,977,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Raymond James & Associates grew its stake in shares of Medpace by 11.9% during the 3rd quarter. Raymond James & Associates now owns 80,422 shares of the company’s stock valued at $12,640,000 after buying an additional 8,562 shares during the period. Forte Capital LLC ADV lifted its holdings in shares of Medpace by 42.6% during the 3rd quarter. Forte Capital LLC ADV now owns 2,680 shares of the company’s stock valued at $421,000 after acquiring an additional 800 shares in the last quarter. Hancock Whitney Corp lifted its holdings in shares of Medpace by 10.9% during the 3rd quarter. Hancock Whitney Corp now owns 45,820 shares of the company’s stock valued at $7,202,000 after acquiring an additional 4,494 shares in the last quarter. First National Bank of Omaha lifted its holdings in shares of Medpace by 85.6% during the 2nd quarter. First National Bank of Omaha now owns 4,856 shares of the company’s stock valued at $727,000 after acquiring an additional 2,240 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in shares of Medpace by 1.3% during the 2nd quarter. Victory Capital Management Inc. now owns 48,109 shares of the company’s stock valued at $7,200,000 after acquiring an additional 639 shares in the last quarter. 82.49% of the stock is owned by hedge funds and other institutional investors.
Medpace Price Performance
Shares of MEDP stock opened at $228.56 on Monday. The firm has a market capitalization of $7.11 billion, a P/E ratio of 35.06 and a beta of 1.42. The company’s fifty day moving average price is $213.31 and its two-hundred day moving average price is $181.97. Medpace Holdings, Inc. has a 12 month low of $126.94 and a 12 month high of $235.72.
In other news, General Counsel Stephen P. Ewald sold 6,500 shares of the company’s stock in a transaction dated Thursday, October 27th. The shares were sold at an average price of $220.53, for a total value of $1,433,445.00. Following the sale, the general counsel now owns 14,854 shares in the company, valued at approximately $3,275,752.62. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 20.60% of the company’s stock.
Analysts Set New Price Targets
Several equities analysts recently weighed in on the stock. Robert W. Baird lifted their target price on shares of Medpace from $217.00 to $226.00 in a report on Friday. StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Friday, October 28th. Finally, UBS Group upgraded shares of Medpace from a “sell” rating to a “neutral” rating and boosted their price objective for the stock from $142.00 to $238.00 in a report on Thursday, October 27th.
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- General Electric Stock, The Sum of All Parts Strategy is Paying Off
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.